Prostate Volume and PSA Cutoff Values as Predictive Indices for Success of Doxazocin Treatment in BPH in GHRDS by Mohamed, M et al.
 




Prostate Volume and PSA Cutoff Values as Predictive Indices for Success of 
Doxazocin Treatment in BPH in GHRDS 
Mohamed Nasr El Din Mohamed 1*, Mustafa Omran 1*  
Mohammed El Imam M. Ahmed 1*, Khalid E Khalid 2*, Elahdi Miskeen 1* 
ABSTRACT 
Background: Benign prostatic hyperplasia (BPH) is a non malignant enlargement of the prostate. 
This study was conducted to determine the pattern of presentation of BPH with and without acute 
urinary retention (AUR) and to determine the risk factors for acute urinary retention, in addition, to 
assess the results of doxazosin in the treatment of BPH with and without AUR. 
Patients and methods: Ninety two patients were enrolled in this study. All patients presented to 
the emergency department and the referred clinic of the Gezira Hospital for Renal Disease and 
Surgery (GHRDS) with lower urinary tract symptoms with and without acute urinary retention 
suggestive of BPH were evaluated according to the European guidelines. All of them underwent 
trans-rectal ultra sound and measurement for the prostatic volume. Serum PSA level was estimated.  
Doxazosin was given to all patients and they were followed for twelve weeks. A trial without a 
catheter at the end of the first week was attempted for patients with acute urinary retention.  
Results: The patients’ mean age ± SD at baseline was 67.8 ± 7.7 and 69.4 ± 9.9 for Non-AUR/BPH 
and AUR/BPH respectively. Comparing baseline clinical parameters of patients with and without 
acute urinary retention revealed that IPSS, prostate volume and PSA level are significantly different 
between the two groups with P< 0.01, 0.01 and 0.00 respectively. In the TWOC, 65% of patients 
passed urine spontaneously. By the end of the study, the overall response of patients showed 78.9% 
successful rate (n=73) and 21.1% failure rate (n=19). Prostatic volume and PSA level were found to 
affect doxazosin treatment significantly. With cutoff values of 41cc and (3.45) ng/ml, prostatic 
volume and PSA level influenced doxazosin treatment failure. 
Conclusion: Serum PSA and prostate volume are powerful predictors of the risk of AUR. Alpha 
blockers are efficacious in treating retaining and non-retaining BPH patients. Knowledge of 
baseline serum PSA and/or prostate volume are useful tools to aid physicians and decision makers 
in predicting the risk of BPH-related outcomes and choosing dexazosin as therapy for BPH. 
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enign prostatic hyperplasia (BPH) is a 
common disease that has been 
reported to occur in 19-30% of men 
older than 50 years1. Long-term consequences 
of the disease may include acute urinary 
retention (AUR) and the need for surgery, as 
well as urinary tract infection, bladder 
function deterioration, and rarely renal failure 
due to obstruction2-4.  
In addition to symptom severity, the serum 
prostate-specific antigen (PSA) level and 
prostate volume (PV) have been described as 
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significant prognostic factors that predict 
treatment outcome in patients with lower 
urinary tract symptoms due to BPH treated 
with either a 5-alpha-reductase inhibitor or 
placebo5–9. 
Alpha blockade became established as a 
therapy for BPH on the basis of its effects on 
symptoms and flow rates. The benefits of α1-
blockade therapy appear shortly after starting 
therapy due to the alteration in dynamic 
smooth muscle tension within the prostate and 
the bladder neck10. With regard to BPH 
progression; a number of studies have 
examined the effect of the α1-blocker 
alfuzosin on the risk of AUR. However, none 
have shown conclusively that there is a risk 
reduction11. 
B
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This study aimed to evaluate the pattern of 
presentation of BPH in Gezira State, Central 
Sudan, and to assess the results of the use of 
doxazosin in both Non-AUR/BPH and 
AUR/BPH patients, as well as, to identify the 
factors that might be associated with the 
clinical progression of the disease on the 
overall response for α1-blockers in the 
treatment of BPH.        
 
MATERIAL AND METHODS 
 
This is a prospective observational analytical 
study conducted in Gezira Hospital for Renal 
Disease and Surgery (GHRDS) in the period 
from June 2006 to December 2006. GHRDS 
provides service for a large number of 
patients in a wide geographical area. We used 
IPSS points ranging from (0-35) for the 
assessment of LUTS. All the study subjects 
gave informed consent to the study, which 
was approved by the Institutional Medical 
Ethics Review Board of the University of 
Gezira. 
Trans-rectal ultra sound was performed to 
estimate the prostatic volume and exclude any 
other co-morbidity. Width, height, and depth 
were measured and the volume calculated 
using the formula; volume = width× height × 
depth × 0.5 (all dimensions measured in cm). 
Physical examinations and routine 
heamtologic and serum chemistry tests were 
performed yearly. Patients receiving alpha 
blocking agents or antiandrogens and patients 
with prostate cancer, prostatitis, previous 
prostate surgery/invasive therapy, clinical 
neurological defect, gross haematuria, bladder 
stone evidenced by U/S or taking anti-
androgen therapy were excluded.  
For the present analysis, all patients were 
given doxazosin (α1-blocker) starting with 
small dose of 1-2 mg and increased to a fixed 
dose of 4 mg to the end of the study. Non 
AUR/BPH were given the drug for 12 weeks 
(six weeks intervals), while the AUR/BPH 
patients were followed for one week without 
catheter intervention. The drug was 
administered to non AUR and to AUR 
patients who successfully passed the urine 
one week after follow up without catheter 
intervention. Responsiveness of treatment was 
indicated by the one level reduction of IPSS 
and completion of the period without 
complications or serious side effects.  
Blood samples were collected in 5 ml sterile 
vacutainers containing ethylene diamine tetra 
acetic acid (EDTA). After blood clotting, the 
samples were centrifuged within 20 minutes 
after collection at 500 x g for 10 min, and sera 
were stored at -20 ºC until assay.  
The total prostate-specific antigens were 
assessed using an immunoradiometric assay 
(Skybio, London, UK) based on two anti-PSA 
antibodies: 125I- labeled and other one as solid 
phase. All tubes were counted for 100 
seconds on multi-well gamma counter and 
data was processed by a computer program. 
The mean, STD and minimum and maximum 
values were calculated and the baseline 
parameters values in (none-AUR) and (AUR) 
groups were analysed using student unpaired 
t-test. Receiver operating characteristic curve 
(ROC) used to test the impact of the prostate 
volume and PSA on the response of those 
patients to doxazosin. Particularly to test their 
implication on patients who did not respond. 
All data were analyzed by using the SPSS 
computer program and the P<0.05 was 
considered to be statistically significant. 
 
RESULTS 
In this study, patients came from different 
nearby and distant states. The majority of 
patients came from the Gezira and central 
states.  BPH patients comprised almost 40% 
of all patients presented to the emergency 
department and referral clinic. 92 Sudanese 
patients complaining of lower urinary tract 
symptoms (LUTS) suggestive of benign 
prostatic hyperplasia (BPH) were included in 
this study. After reviewing and analyzing the 
pattern of presentation, we found that 21.7% 
(n=20) of patients presented with acute 
urinary retention due to benign prostatic 
hyperplasia (AUR/BPH) while 78.3% (n=72) 
of patients presented with symptoms of 
benign prostatic hyperplasia without acute 
urinary retention (Non-AUR/BPH). 
The patients’ mean age ± SD at baseline was 
67.8 ± 7.7 and 69.4 ± 9.9 for Non-AUR/BPH 
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and AUR/BPH respectively, and the follow 
up was 12 weeks for the doxazosin (α1-
blocker). A significant deference (P< 0.01) 
was reported for the mean of total IPSS points 
at baseline for AUR/BPH and Non AUR/BPH 
which were 27.5 ± 7.8 and 21.8 ± 6.1 
respectively (Table 1).  
 
Table (1): Illustrating different parameters in 









































Significant p value less than 0.05 
 
Prostate volume was measured by transrectal 
ultrasound, the frequency of prostate volume 
measured >40cc comprises 45.8% for patients 
with Non-AUR/BPH and 75% for patients 
with AUR/BPH, the frequency of prostate 
volume and the presentation of IPSS in Non-





Table (2): The frequency of different groups 
of prostate volume in Non-AUR/BPH patients 










Less than 20cc 1.4 0 1.1% 
20cc – 40cc 52.8 25.0 46.7% 
>40cc 45.8 75 52.2% 
 
P value 0.037  
 
In this study, as shown in Table 1, there is a 
significant difference in the mean of prostate 
volume and the PSA level (P<0.01 & P< 
0.00) between Non-AUR/BPH (43.4 ± 15.6 cc 
& 3.4 ± 2.1 ng/ml) and AUR/ BPH (55.3 ± 
25.1 cc & 5.7 ± 2.7 ng/ml) respectively.  
In a trial without a catheter (TWOC) after one 
week of treatment by doxazosin, 65% (13/20) 
of the AUR/BPH patients succeeded in 
passing urine spontaneously and continued to 
have the drug to the end of the period of the 
study, while 35% (7/20) of them failed to do 
that and stopped taking the drug and treated 
surgically. 
 
A total of 85 BPH patients (72 with Non-
AUR/BPH, 13 with AUR/BPH) were 
followed up for 12 weeks and their response 
to doxazosin was assessed by the IPSS points 
(Figure 1) and the reduction of the 
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Figure (2): Response of different obstructive symptoms (IPSS) in Non-AUR/BPH patients (n=72) 
 
Prostatic volume and PSA levels were tested 
to identify their impact and magnitude on 
determining the state of non-response which 
showed by those 16% (10/72) of patients with 
Non-AUR/BPH and 10% (2/13). There is a 
significant difference (P<0.01) in the mean of 
PSA between responded (3.2 ± 1.8 ng/ml) and 
non responded (5.1 ± 2.1 ng/ml) Non-
AUR/BPH patients. While the prostate 
volume reported significant difference 
(P<0.05) between AUR/BPH patients 
responded or not responded to TWOC            
(Table 3). 
 
Table (3): Means of the PSA level and prostate volume in AUR and Non-AUR/BPH patients who 
responded and did not respond to doxazosin. 
 
 
BPH at presentation 
Responded to treatment Did not responded to 
treatment at 12 weeks 
No (%) Mean ± SD No 
(%) 
Mean ± SD 
Non-AUR/BPH 
(n=72) 
PSA level  
62 (86) 
 
3.2 ± 1.8  
10 
(14) 
5.1 ± 2.8* 
Prostate 
Vol. 
43.2 ± 16.0 44.8 ± 13.3 
AUR/BPH (n=20) PSA level 11 (55)  9 (45)  
TWOC 13 (65)  7 (35)  
 
We used the ROC curve also to test the 
sensitivity of measuring the prostatic volume 
and the baseline PSA level in determining the 
state of no response to treatment with 
doxazosin. As shown in (Figure 3), the two 
lines representing the two tests appear to the 
left of the reference diagonal line and close to 
the Y axis (sensitivity), which confirms their 
sensitivity in determining doxazosin treatment 
failure. Area under the curve for the prostatic 
volume measurement is 0.663 and the cutoff 
value selected is ≥ 41cc, above which the 
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Baseline 6 weeks 12 weeks
Baseline 3.43 1.9 2.76 3.08
6 weeks 1.67 0.79 1.36 1.49
12 weeks 0.81 0.44 0.88 1.01
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Figure (3): ROC curve illustrating sensitivity of the PSA level and the prostatic volume in 
determining the state of non response to doxazosin 
 
The estimated area under the curve for PSA 
level is 0.783 and the cutoff value selected is 
≥ 3.45ng/ml. The probability for doxazosin 
treatment failure increases in levels more than 
that.            
Discussion: 
Serum PSA is currently the most widely used 
marker for prostate cancer detection, and a 
yearly measurement is recommended in men 
older than 50 years to aid in the early 
detection of prostate cancer. The observation 
that there is a strong loglinear relationship 
between serum PSA and prostate volume in 
men with BPH12 has led us to consider that 
PSA may also predict those men at increased 
risk of developing AUR or needing BPH 
related surgery. 
BPH presentation with severe symptoms and 
complication can only be explained by the 
lack of knowledge about the disease among 
patients and junior doctors. The small size of 
the sample might give an explanation but still 
there is a high rate of late presentation. The 
observed high level of IPSS severity 
associated with patients with AUR/BPH is 
comparable to results considered severe IPSS 
as one of the strong predictors for BPH 
progression13, 14. 
Prostate volume was found to be different in 
patients with BPH with and without AUR. 
Larger volumes are more frequent among 
patients with AUR. This difference is 
statistically highly significant. In addition, we 
observed statistically significant correlation 
between prostate volume and PSA level (p 
value 0.00). Larger prostate volume was also 
found to be more in AUR/BPH patients who 
did not respond to doxazosin (p< 0.05). 
Therefore, we can consider prostate volume 
as a predictor for BPH disease progression 
and a factor that influence response to 
doxazosin treatment. In our study, we found 
strong correlation between PSA and the 
prostate volume estimated by TRUS. In this 
study, PSA level of 4-10 ng/ml was 
considered highly suggestive for BPH. When 
we subjected PSA level in patients with BPH 
(with or without AUR) we observed higher 
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volume
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levels of PSA in the group with Non-
AUR/BPH and it was highly statistically 
significant (p< 0.01). In the AUR/BPH 
patients we observed failure of trial without a 
catheter (TWOC) in 35% of patients who 
received doxazosin 4 mg orally. Another 10% 
of them showed no response and needed re- 
catheterization at the end of the study. In the 
literature, α-blockers like; 
phenoxybenzamine, Terazosin, tamsulozin, 
doxazosin and alfuzosin were tried to manage 
AUR. Nowadays, TWOC recommended as 
the first line of treatment for AUR/BPH in all 
patients. Our study gives estimation to the 
initial response of those patients to doxazosin 
and carried a short period of follow up to 
determine the maintenance of treatment 
without the need for re-catheterization. We 
think it needs longer period of follow up to 
determine the long-term effect of doxazosin in 
the treatment of patients with AUR/BPH. In 
this group of patients prostate volume 
estimated by trans-rectal ultrasound are 
significantly influencing the early failure of 
TWOC and we observed larger prostate 
volumes in AUR/BPH patients who failed to 
pass urine spontaneously after one week of 
treatment. In addition, PSA was found to be 
significantly high in patients who did not 
respond to doxazosin in the first week in 
comparison to those who responded. Age and 
IPSS were not statistically significant like 
prostate volume and PSA. Therefore, we 
considered PSA and prostate volume as 
strong predictors to TWOC (with doxazosin) 
failure in patients with AUR/BPH. In our 
study, the results of TWOC are more or less 
comparable to the results reached by many 
researchers15-17. 
In the Non-AUR/BPH patients, at the end of 
the study (12 weeks), 86.1% of patients 
responded well to treatment by doxazosin and 
showed marked and statistically significant 
reduction in IPSS points. However, doxazosin 
treatment maintained without serious side 
effects and complications. In the literature, a 
multi centre controlled trial conducted in 
Egypt to evaluate response to doxazosin; they 
reported improvement of the IPSS points 
from 19.55 (SD 5.27) to 9.25 (SD 3.77)18.  
In our study improvement in the IPSS points 
is from 21.8 (SD 6.09) to 6.7 (SD 7.2) at the 
end of the period. We observed side effects in 
15% of patients. Despite the difference 
between our study which is an observational 
one, and that study which is an interventional 
one, results look comparable. The observed 
high rate of side effects in our study is 
probably due to the nature of the study, in 
which the criteria are more flexible accepting 
any complaint without critical measurement. 
While in the controlled trials more rigid 
criteria were implemented and more critical 
measurements were applied. When testing 
prostate volume and PSA level, we found 
patients with higher PSA levels didn’t 
respond to doxazosin treatment with 
significant statistical difference between the 
two groups (p<0.01). Regarding the prostate 
volume we found it insignificant. 
Previous studies have made a conclusion that 
serum PSA and prostate volume are powerful 
predictors of AUR and the need for BPH-
related surgery5, 19. More over, Kurita 
confirmed that prostate volume and PSA 
predict treatment failure by tamsulozin20. 
In our study, we used the ROC curve, which 
confirmed the sensitivity of prostate volume 
and PSA in determining the probabilities of 
doxazosin treatment failure. A cutoff value of 
prostate volume of 41cc was proposed, above 
which we expect high probability of 
doxazosin treatment failure. On the other 
hand, 3.45ng/ml was proposed as a cutoff 
value for PSA. PSA level > 3.45 ng/ml carries 
high probability of doxazosin treatment 
failure. There is no agreement about the cutoff 
values above which we shift from doxazosin 
to other drug therapy or to surgery. According 
to the general consensus, 40cc volume 
considered as a cutoff value above which anti-
androgen therapy is recommended. In one 
meeting, pioneers of urology who 
investigated this issue presented their 
experiences12. Roehrborn considered PSA 
>3.2 ng/ml and prostate volume >50cc as an 
indication for anti-androgen therapy. Lowe 
proposed prostate volume of >70cc and Lepor 
proposed >50cc as cutoff value. More 
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controlled studies are needed to evaluate these 
cutoff values. 
Conclusion Prostatic volume and PSA level 
were found to be powerful predictors of the 
success of doxasocin treatment for BPH. A 
prostate volume of 41cc or less and a PSA 
level of (3.45) ng/ml constitute the cutoff 
values for the best response for doxasocin. 
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